COVID-19 vaccine maker Novavax raised doubts yesterday about its ability to continue its business, announcing plans to cut spending after struggles in rolling out its coronavirus jab.
Shares of Novavax plummeted 25% in extended trading, after the company reported fourth-quarter earnings that missed analyst estimates.